Neuroplast Develops Safer Stem Cell Therapy For Spinal Injuries
Unique Autologous Approach
Executive Summary
Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.
You may also be interested in...
CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
Pharming’s Leniolisib On Track To Become First Disease-Modifying APDS Drug
The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.
Peptilogics’ AI Peptide Platform Could Help Address Orthopedic Unmet Need
Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.